|MetaStat disclosed selling 36% of its non-brokered mezzanine financing. The company launched a $600,000 investment round subscribed so far by six investors. The subscription which raised $215,000 started one month ago. The offering will remain open until May 2015 while an additional $385,000 worth of securities is sold to investors. A total of five unregistered securities offerings closed by the company raised an estimated $15 million.
MetaStat trades under symbol OTC: MTST
|The company is a development stage life sciences organization that develops and commercializes diagnostic products and novel therapeutics for the early and prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.|
|The company is headquartered in Montclair NJ. MetaStat kept its revenues undisclosed.
The executive team includes Daniel Schneiderman, Oscar Bronsther and Warren Lau.
The board of directors includes David Epstein, David Siegel, Johan (thijs) Spoor and Patrick Mooney.The company has raised an estimated total of $15.22 million via private unregistered security offerings.
Status: First close
Amount offered: $600,000
Amount placed: $215,000
First sale: 05-22-2014
Data as of: 06-20-2014